ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 689

Activation of the Interferon Pathway Is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients

Kichul Ko1, Yelena Koldobskaya1, Elizabeth Rosenzweig2 and Timothy B. Niewold1, 1Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 2Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies, ethnic studies and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Gene expression studies have been instrumental in defining important aspects of the complex immunological pathogenesis in systemic lupus erythematosus (SLE) which is a heterogeneous disease that manifests differently by ancestry, and by the presence of autoantibodies directed at RNA binding proteins (anti-RBP).  Moreover, anti-RBP antibodies are associated with high serum interferon (IFN)-α, which plays an important role in pathogenesis of SLE.   Our overall hypothesis was that the molecular pathogenesis of SLE differs between African-American (AA) and European-American (EA) SLE patients, and between those with anti-RBP antibodies and those who lack these antibodies.  We aimed to explore this hypothesis using peripheral blood gene expression profiling.

Methods: Whole blood RNA from 33 female SLE patients and 16 matched female controls from AA and EA ancestral backgrounds was analyzed on Affymetrix Gene 1.0 ST gene expression arrays.  Two-tailed t-tests were performed to compare the expression values between cases and controls in each ancestry.  Differentially expressed genes with a cutoff P of 0.05 were further explored using Ingenuity Pathway Analysis (IPA) to compare the top canonical pathways amongst the sample groups.  An independent replication cohort of more than 100 SLE patient samples and 30 controls was used to test the hypotheses generated by the microarray data, using qPCR to quantify gene expression. 

Results: Both AA and EA female (AAF and EAF respectively) patients with positive anti-RBP antibodies (RBP+) showed similar IFN-related canonical pathways such as IFN Signaling (P = 1.3 x 10-7 and 6.3 x 10-11 in AAF vs. EAF patients respectively), Antigen Presenting Pathway (P = 1.8 x 10-5 and 2.5 x 10-6) and a number of pattern recognition receptor pathways.  The key pathway difference was shown between AAF and EAF patients with negative anti-RBP antibodies (RBP-) as EAF patients also showed IFN Signaling (P = 1.0 x 10-5) and Antigen Presenting Pathway (P = 1.3 x 10-11) whereas AAF patients with RBP- did not reveal any IFN-related pathways.  A replication study was performed through qPCR on 3 IFN-inducible genes, IFIT1, MX1 and PKR, and showed similar results.  All three genes were strongly up-regulated in RBP+ patients in both ancestries, and PKR was up-regulated in EAF patients with RBP- but these findings were completely absent in AAF patients with RBP-.

Conclusion: Our data show that IFN-induced gene expression is completely dependent on the presence of autoantibodies in AA SLE patients but not in EA patients.  Further studies are needed to explore other novel pathways that may define the heterogeneity in SLE, especially in the RBP- AA group.


Disclosure:

K. Ko,
None;

Y. Koldobskaya,
None;

E. Rosenzweig,
None;

T. B. Niewold,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activation-of-the-interferon-pathway-is-dependent-upon-autoantibodies-in-african-american-sle-patients-but-not-in-european-american-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology